Peter Steiner
Fondatore presso PreComb Therapeutics AG
Profilo
Peter Steiner is the founder of PreComb Therapeutics AG.
He is currently a Member-Supervisory Board at Insilico Biotechnology AG.
Previously, he worked at ESBATech AG as an Executive Director-Production & Processes from 2013 to 2017.
Dr. Steiner obtained his undergraduate and doctorate degrees from the Swiss Federal Institute of Technology.
Posizioni attive di Peter Steiner
Società | Posizione | Inizio |
---|---|---|
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | Direttore/Membro del Consiglio | - |
PreComb Therapeutics AG
PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | Fondatore | 01/01/2018 |
Precedenti posizioni note di Peter Steiner
Società | Posizione | Fine |
---|---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | 01/09/2017 |
Formazione di Peter Steiner
Swiss Federal Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million. | Technology Services |
PreComb Therapeutics AG
PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Peter Steiner